Cytokeratin 5/8 Antibody (RCK102): sc-32328

Cytokeratin 5/8 Antibody (RCK102) is a mouse monoclonal IgG1 kappa light chain antibody that detects Cytokeratin 5/8 of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and flow cytometry (FCM). Anti-Cytokeratin 5/8 antibody (RCK102) is available in both non-conjugated and various conjugated forms, including phycoerythrin (PE) and fluorescein isothiocyanate (FITC), providing flexibility for diverse experimental needs. Cytokeratin 5 and 8 are crucial components of the cytoskeleton in epithelial cells, forming intermediate filaments that contribute to structural integrity and mechanical resilience of tissues. These cytokeratins maintain stability of basal cells in stratified epithelia, essential for barrier function and protection against environmental stressors. Expression patterns of Cytokeratin 5 and 8 serve as valuable biomarkers for distinguishing between different types of epithelial tumors, aiding in diagnosis and characterization of malignancies. Mutations in KRT5 can lead to epidermolysis bullosa, a genetic disorder resulting in fragile skin, highlighting Cytokeratin 5/8′s significance in normal physiology and disease states. Cytokeratin 5 is predominantly expressed in basal cells, while Cytokeratin 8 appears in various epithelial tissues and tumors, including adenocarcinomas, making Cytokeratin 5/8 (RCK102) monoclonal antibody an essential tool for studying epithelial biology and cancer pathology.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Cytokeratin 5/8 Antibody (RCK102) References:

1. True cytokeratin 8/18 immunohistochemistry is of no use in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study.  |  Hsu, JD., et al. 2010. Int J Gynecol Pathol. 29: 282-9. PMID: 20407331
2. Cytokeratin-8 in Anaplastic Thyroid Carcinoma: More Than a Simple Structural Cytoskeletal Protein.  |  Guo, D., et al. 2018. Int J Mol Sci. 19: PMID: 29443941
3. Cytokeratin 5/6 expression in bladder cancer: association with clinicopathologic parameters and prognosis.  |  Hashmi, AA., et al. 2018. BMC Res Notes. 11: 207. PMID: 29587848
4. Biological significance of GATA3, cytokeratin 20, cytokeratin 5/6 and p53 expression in muscle-invasive bladder cancer.  |  Wang, CC., et al. 2019. PLoS One. 14: e0221785. PMID: 31469885
5. Cytokeratin 5 alters β-catenin dynamics in breast cancer cells.  |  McGinn, O., et al. 2020. Oncogene. 39: 2478-2492. PMID: 31988452
6. Cytokeratin 5 and cytokeratin 20 inversely correlate with tumour grading in Ta non-muscle-invasive bladder cancer.  |  Muilwijk, T., et al. 2021. J Cell Mol Med. 25: 7890-7900. PMID: 34184816
7. Inhibition of Notch activity promotes pancreatic cytokeratin 5-positive cell differentiation to beta cells and improves glucose homeostasis following acute pancreatitis.  |  Zhang, X., et al. 2021. Cell Death Dis. 12: 867. PMID: 34556631
8. Utility of D2-40, Cytokeratin 5/6, and High-Molecular-weight Cytokeratin (Clone 34βE12) in Distinguishing Intraductal Spread of Urothelial Carcinoma From Prostatic Stromal Invasion.  |  Iakymenko, OA., et al. 2022. Am J Surg Pathol. 46: 454-463. PMID: 34560681
9. Antimicrobial peptide nisin induces spherical distribution of macropinocytosis-like cytokeratin 5 and cytokeratin 17 following immediate derangement of the cell membrane.  |  Kitagawa, N. 2022. Anat Cell Biol. 55: 190-204. PMID: 34903675
10. Increase of KLK7, cytokeratin 5/6, and elafin expression in head and neck squamous cell carcinoma compared with lung squamous cell carcinoma.  |  Shanmugam, A., et al. 2024. J Histotechnol. 47: 80-86. PMID: 38189409

The preferred Cytokeratin 5 antibody is Cytokeratin 5 Antibody (RCK103): sc-32721.